Status:
RECRUITING
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Lead Sponsor:
Eli Lilly and Company
Conditions:
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...
Eligibility Criteria
Inclusion
- Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:
- receiving study intervention
- in the short-term follow-up period, or
- in the long-term follow-up period
Exclusion
- Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2032
Estimated Enrollment :
279 Patients enrolled
Trial Details
Trial ID
NCT06876662
Start Date
May 20 2025
End Date
December 1 2032
Last Update
December 4 2025
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136-1002
2
Florida Cancer Specialists
Sarasota, Florida, United States, 34232-6422
3
The Emory Clinic
Atlanta, Georgia, United States, 30322-1013
4
Northwestern University
Chicago, Illinois, United States, 60611-3013